OXALTERO 50 MG

The defining feature of Oxaliplatin is its platinum compound activity. Forms DNA cross-links that inhibit replication and transcription. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. Within this database it is listed under Chemotherapy; Platinum-Based Chemotherapy. The principal indications are Colorectal cancer; selected gastric/pancreatic and other GI cancers, with Colorectal; Gastric; Pancreatic identified as the associated tumor types. Its treatment role can differ substantially between these settings, so the disease context matters as much as the drug class. Regimens listed for the medicine include FOLFOX; CAPOX/XELOX; FOLFIRINOX. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Where a molecular alteration, receptor status, or prior-treatment requirement appears in the indication, that criterion is part of the clinical context rather than an optional detail. The medicine may consequently occupy an induction, maintenance, adjuvant, metastatic, salvage, or supportive position depending on the setting recorded here. The summary is descriptive and does not provide individualized dosing or administration instructions. Current product information and disease-specific guidance should be checked before clinical application.